BusinessActinium Pharmaceuticals Selects Vector Oncology as its Clinical Research Organization for Actimab-A Phase 2 TrialBy Nasdaq OMXSep 20, 2016, 11:02 AM UTC
BusinessActinium Pharmaceuticals to Present at Ladenburg Thalmann 2nd Annual Healthcare ConferenceBy Nasdaq OMXSep 19, 2016, 11:00 AM UTC
BusinessActinium Pharmaceuticals Presenting at Rodman & Renshaw 18th Annual Global Investment ConferenceBy Nasdaq OMXSep 13, 2016, 11:00 AM UTC
BusinessActinium Pharmaceuticals Presenting at the BioCentury 23rd Annual NewsMakers in the Biotech Industry ConferenceBy Nasdaq OMXSep 9, 2016, 11:00 AM UTC
BusinessActinium Enhances Capabilities with Hiring of Industry and Clinical Research Veterans to its Product Development and Clinical Development TeamsBy Nasdaq OMXSep 7, 2016, 11:00 AM UTC
BusinessPeregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred StockBy Nasdaq OMXSep 6, 2016, 8:05 PM UTC
BusinessNational Comprehensive Cancer Network (NCCN) Awards Three Grants for Combination Studies of Peregrine Pharmaceuticals’ Bavituximab in Multiple CancersBy Nasdaq OMXSep 6, 2016, 12:45 PM UTC
BusinessPeregrine to Report Financial Results for First Quarter of Fiscal Year 2017 After Market Close on September 8, 2016By Nasdaq OMXSep 1, 2016, 8:05 PM UTC
